Phase 3 Trial of TQB2868 and Anlotinib in Metastatic Pancreatic Cancer Initiated
A randomized, open-label trial is underway to evaluate TQB2868 injection and anlotinib hydrochloride in combination with chemotherapy versus placebo.
Company
Pharmaceutical intelligence for TQB Biopharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.